Loncar Cancer Immunotherapy ETF (CNCR)

Delayed Data
As of Sep 13
 +0.0599 / +0.30%
Today’s Change
Today|||52-Week Range

Investment Objective

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.

No recent news for Loncar Cancer Immunotherapy ETF.


1 month+0.40% 3 years-6.15%
3 months-1.39% 5 years--
1 year-18.50% Since inception-5.17%
Data through 09/14/2019

Quote Details

Previous close$19.93
Open day’s range19.92 – 20.13
Net asset value (NAV)19.94 (09/13/2019)
Daily volume3,838
Average volume (3 months)8,370
Data as of 3:09pm ET, 09/13/2019

Peer Comparisonvs. Health ETFs

Performance 5-yr return--+9.15%
Expense Gross exp ratio0.79%1.24%
Risk 5 year sharpe ratio--0.46
Net assets$34.2M$3.0B
Average market cap$4.9B$36.1B
Average P/E--24.1
Dividend / Share--0.26%


FHLC Fidelity® MSCI Health Care Index ETF
VHT Vanguard Health Care Index Fund ETF Shar...
IHI iShares U.S. Medical Devices ETF


Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
-- 5.34%
YMAB Y-mAbs Therapeutics, Inc5.02%
-- 4.89%
-- 4.75%
XNCR Xencor Inc4.74%
-- 4.71%
IOVA Iovance Biotherapeutics Inc4.48%
SGEN Seattle Genetics Inc4.35%
MRK Merck4.34%
-- 4.31%